Intralesional vinblastine for cutaneous Kaposi's sarcoma associated with acquired immunodeficiency syndrome. A clinical trial to evaluate efficacy and discomfort associated with infection.

Boudreaux AA, Smith LL, Cosby CD, Bason MM, Tappero JW, Berger TG.

J Am Acad Dermatol. 1993 Jan;28(1):61-5. doi: 10.1016/0190-9622(93)70010-q.

BACKGROUND: Intralesional vinblastine has been used to treat Kaposi's sarcoma associated with acquired immunodeficiency syndrome (AIDS-KS). Injections are painful and anticipated response rates are not well documented. OBJECTIVE: Eleven homosexual men were studied to evaluate the efficacy and pain associated with intralesional vinblastine with or without 1% bicarbonate buffered lidocaine (BBL). METHODS: Six lesions on each patient were selected and treated with either vinblastine, vinblastine mixed with BBL, or vinblastine 5 minutes after BBL injection. Control lesions received BBL, saline, or no treatment. Patients recorded injection pain on a visual analog scale. RESULTS: There was a complete or partial clinical response in 88% of vinblastine-treated lesions. Pain scores for BBL, vinblastine, and the mixture of BBL and vinblastine were not statistically different. CONCLUSION: Intralesional vinblastine is effective therapy for AIDS-KS. Local anesthesia does not reduce efficacy of treatment, or reduce the pain experienced by the patient.

PMID: 8381146

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.